NCT05525247
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05525247
Title A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Selecxine
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | AUS

Facility Status City State Zip Country Details
Selecxine Investigator site Sarasota Florida 34232 United States Details
Selecxine Investigator site Detroit Michigan 48201 United States Details
Selecxine Investigator site Oklahoma City Oklahoma 73104 United States Details
Selecxine Investigator site Waratah New South Wales 2298 Australia Details
Selecxine Investigator site Brentwood Perth 6153 Australia Details
Selecxine Investigator site Seoul Jongno-gu 03080 South Korea Details
Selecxine Investigator site Seoul Seodaemun-gu 03722 South Korea Details
Selecxine Investigator site Gyeonggi-do Seongnam-si 13620 South Korea Details
Selecxine Investigator site Seoul Songpa-gu 05505 South Korea Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field